ASH 2025 | Practice-changing abstracts from ASH 2025 for community oncologists treating NHL and CLL

I think what we saw yesterday morning with the presentation of epcor R-squared in the second line by Dr Falchi, I think this is going to be a game changer. I really do, you know, as a lymphoma physician, I really think that that novel combination, just with the efficacy data, the safety data, I really think is going to be a practice-changing, you know, therapy for us, you know, in the near future. Well, hopefully soon, but we all know it takes, there’s always a little bit of a lag, but hopefully that’s going to be something that we’re using. 

In terms of CLL, I think, you know, really kind of, you know, talking about AMPLIFY and the novel combinations of, you know, acala-ven, as we saw with CLL17, right, looking at another oral agent combination. Really, I think it’s important to realize that we are definitely moving away, you know, from what we thought was norm with IV therapies and things like that and getting into all oral-based regimens. Again, we’ll see what the adoption is like. And, you know, again, these patients are in the community, so we have to educate on the new novel therapies and both with epcor R-squared in non-Hodgkin’s and then with our BTK, BCL2 inhibitors in CLL. But I do think that, and those are just two of the things that we’ve seen here – I mean, it’s been a really great meeting – but just things that I think are going to start replacing some of our, you know, our oldies but goodies.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.